Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Sylvie Négrier, David Pérol, Rastislav Bahleda, Antoine Hollebecque, Etienne Chatelut, Helen Boyle, Philippe Cassier, Séverine Metzger, Ellen Blanc, Jean-Charles Soria, Bernard Escudier

ABSTRACT

BACKGROUND: Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal antibody have been registered for clinical use in advanced renal cell carcinoma. The VEGFR TKI, pazopanib, with a rather manageable toxicity profile, was preferred to sunitinib by mRCC patients. We investigate the combination of pazopanib and bevacizumab to determine the maximum tolerated dose (MTD) in mRCC and other advanced solid tumors. METHODS: In this bicentric phase I trial with a 3 + 3 + 3 dose-escalation design, patients received oral pazopanib once daily plus intravenous infusion of bevacizumab every 2 weeks from D15, at one of the four dose levels (DL) planned according to the occurrence of dose limiting toxicities (DLT). 400 and 600 mg pazopanib were respectively combined with 7.5 mg/kg bevacizumab in DL1 and DL2, and 600 and 800 mg pazopanib with 10 mg/kg bevacizumab in DL3 and DL4. Tumor response was evaluated every 8 weeks. Blood samples were assayed to investigate pazopanib pharmacokinetics. RESULTS: Twenty five patients including seven mRCC were enrolled. Nine patients received the DL1, ten received the DL2. No DLT were observed at DL1, five DLT at DL2, and 3 DLT in the six additional patients who received the DL1. A grade 3 microangiopathic hemolytic anemia syndrome was observed in four (16%) patients. Five (22%) patients achieved a partial response. The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion. CONCLUSIONS: The combination of pazopanib and bevacizumab induces angiogenic toxicity in patients without any pre-existing renal or vascular damage. Even if a marginal efficacy was reported with five (22%) patients in partial response in different tumor types, the toxicity profile compromises the development of this combination. TRIAL REGISTRATION: The study was retrospectively registered on ClinicalTrials.gov (number NCT01202032 ) on 2010, Sept 14th. More... »

PAGES

547

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-017-3527-7

DOI

http://dx.doi.org/10.1186/s12885-017-3527-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091206574

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28810837


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Monitoring", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "University Lyon, Universit\u00e9 Claude Bernard Lyon 1, Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "N\u00e9grier", 
        "givenName": "Sylvie", 
        "id": "sg:person.0723756046.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Clinical Research and Innovation Department, Centre L\u00e9on B\u00e9rard, F-69373, Lyon, Cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "P\u00e9rol", 
        "givenName": "David", 
        "id": "sg:person.01221677717.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221677717.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "DITEP -D\u00e9partement d\u2019Innovation Th\u00e9rapeutiques et Essais Pr\u00e9coces, Institut  Gustave Roussy, 94805, Villejuif Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bahleda", 
        "givenName": "Rastislav", 
        "id": "sg:person.012307334207.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012307334207.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "DITEP -D\u00e9partement d\u2019Innovation Th\u00e9rapeutiques et Essais Pr\u00e9coces, Institut  Gustave Roussy, 94805, Villejuif Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hollebecque", 
        "givenName": "Antoine", 
        "id": "sg:person.0602246235.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602246235.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Paul Sabatier University", 
          "id": "https://www.grid.ac/institutes/grid.15781.3a", 
          "name": [
            "Institut Claudius Regaud, Inserm UMR1037 CRCT, Universit\u00e9 Paul-Sabatier, 20/24 rue du Pont Saint-Pierre, 31052, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chatelut", 
        "givenName": "Etienne", 
        "id": "sg:person.01333606250.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333606250.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Medical Oncology Department, Centre L\u00e9on B\u00e9rard, F-69373, Lyon, Cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boyle", 
        "givenName": "Helen", 
        "id": "sg:person.0616261742.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616261742.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Medical Oncology Department, Centre L\u00e9on B\u00e9rard, F-69373, Lyon, Cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cassier", 
        "givenName": "Philippe", 
        "id": "sg:person.01312356242.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312356242.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Medical Oncology Department, Centre L\u00e9on B\u00e9rard, F-69373, Lyon, Cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Metzger", 
        "givenName": "S\u00e9verine", 
        "id": "sg:person.011242133047.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011242133047.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Medical Oncology Department, Centre L\u00e9on B\u00e9rard, F-69373, Lyon, Cedex 08, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blanc", 
        "givenName": "Ellen", 
        "id": "sg:person.01356177754.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356177754.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Paris-Sud", 
          "id": "https://www.grid.ac/institutes/grid.5842.b", 
          "name": [
            "University of Paris Sud, Orsay, Institut Gustave Roussy, 94805, Villejuif Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soria", 
        "givenName": "Jean-Charles", 
        "id": "sg:person.01225022325.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225022325.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Department of Medical Oncology, Institut Gustave Roussy, 114, rue Edouard-Vaillant, 94805, Villejuif Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "Bernard", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2004.11.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000451221"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.10.8332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000481419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.06.121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001303596"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1309748", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006159778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.21.6994", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006983294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa061884", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008302687"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-2535", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009131859"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-013-9976-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010470509", 
          "https://doi.org/10.1007/s10637-013-9976-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-013-9976-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010470509", 
          "https://doi.org/10.1007/s10637-013-9976-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-013-9976-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010470509", 
          "https://doi.org/10.1007/s10637-013-9976-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-013-9976-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010470509", 
          "https://doi.org/10.1007/s10637-013-9976-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(07)61904-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010511397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00325-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011519120"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-013-2373-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011745965", 
          "https://doi.org/10.1007/s00280-013-2373-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2455-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012606735", 
          "https://doi.org/10.1007/s00280-014-2455-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa032691", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014051315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.60.9727", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016822150"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-0717", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018539077"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdm454", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018847020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa021491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020803009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(07)70037-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021597703"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00240-003-0346-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023624302", 
          "https://doi.org/10.1007/s00240-003-0346-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-2740", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025063112"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.11.5154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027241718"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-13-0708", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029146743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1303989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030656737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30107-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031150467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa072113", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033842397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0707330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036840499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa066838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037798278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/0284186x.2013.782103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039366876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)60651-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040046880"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2013.06.042", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040912245"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.9847", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041483211"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2479-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041617704", 
          "https://doi.org/10.1007/s00280-014-2479-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70124-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046924268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e3181c7307e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047443465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-1275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047556241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00290-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048871630"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.0108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049557004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61613-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052713041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.9764", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052849919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.50.8267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053397983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0708857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053513212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.29187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072293145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra1601333", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074211544"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "BACKGROUND: Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal antibody have been registered for clinical use in advanced renal cell carcinoma. The VEGFR TKI, pazopanib, with a rather manageable toxicity profile, was preferred to sunitinib by mRCC patients. We investigate the combination of pazopanib and bevacizumab to determine the maximum tolerated dose (MTD) in mRCC and other advanced solid tumors.\nMETHODS: In this bicentric phase I trial with a 3\u00a0+\u00a03\u00a0+\u00a03 dose-escalation design, patients received oral pazopanib once daily plus intravenous infusion of bevacizumab every 2 weeks from D15, at one of the four dose levels (DL) planned according to the occurrence of dose limiting toxicities (DLT). 400 and 600\u00a0mg pazopanib were respectively combined with 7.5\u00a0mg/kg bevacizumab in DL1 and DL2, and 600 and 800\u00a0mg pazopanib with 10\u00a0mg/kg bevacizumab in DL3 and DL4. Tumor response was evaluated every 8 weeks. Blood samples were assayed to investigate pazopanib pharmacokinetics.\nRESULTS: Twenty five patients including seven mRCC were enrolled. Nine patients received the DL1, ten received the DL2. No DLT were observed at DL1, five DLT at DL2, and 3 DLT in the six additional patients who received the DL1. A grade 3 microangiopathic hemolytic anemia syndrome was observed in four (16%) patients. Five (22%) patients achieved a partial response. The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) \u03bcg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) \u03bcg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion.\nCONCLUSIONS: The combination of pazopanib and bevacizumab induces angiogenic toxicity in patients without any pre-existing renal or vascular damage. Even if a marginal efficacy was reported with five (22%) patients in partial response in different tumor types, the toxicity profile compromises the development of this combination.\nTRIAL REGISTRATION: The study was retrospectively registered on ClinicalTrials.gov (number NCT01202032 ) on 2010, Sept 14th.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-017-3527-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors", 
    "pagination": "547", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "dc58ef9d3d7658c236388b94c962245d927321db9b75adec9773af9d70ae4f9d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28810837"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-017-3527-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091206574"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-017-3527-7", 
      "https://app.dimensions.ai/details/publication/pub.1091206574"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113667_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-017-3527-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3527-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3527-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3527-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3527-7'


 

This table displays all metadata directly associated to this object as RDF triples.

358 TRIPLES      21 PREDICATES      91 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-017-3527-7 schema:about N0f7724da3a4c4717a3af24f12038de14
2 N0fafbce12d7a4ab8b89e6850e71caa3f
3 N17dfe252055442bf9240065f332cc184
4 N25250acb70dd4cd0853084b3b3f044ec
5 N2599413de8b84b66b7932bd36732f922
6 N2941413c830b460d840ba8ce5ac01362
7 N3227aa7f77e44a3b8a0b49086aaeddd3
8 N36886ec7413e43b19881d0bf903d39f0
9 N392abedf434c4d929789479aa887b75c
10 N75c3793e58064b098059c7f221033215
11 Nc5a6260810d94f6ea53190c5db5c1bb0
12 Nd64aa83d5e02413a9d60f09cb16fe1af
13 Nf364c7ca48824563b44efc9d2a666679
14 Nfb66508769374dd9beacaf3b12879317
15 Nfda06d92fb144fe9ac2ec288986f8b07
16 Nff1e9da37dbc4d6f96512550dd2ae904
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N023a7f49589b44edb857ec9bc06d3ba0
20 schema:citation sg:pub.10.1007/s00240-003-0346-x
21 sg:pub.10.1007/s00280-013-2373-9
22 sg:pub.10.1007/s00280-014-2455-3
23 sg:pub.10.1007/s00280-014-2479-8
24 sg:pub.10.1007/s10637-013-9976-1
25 https://doi.org/10.1016/j.ejca.2008.10.026
26 https://doi.org/10.1016/j.ejca.2013.06.042
27 https://doi.org/10.1016/s0140-6736(07)61904-7
28 https://doi.org/10.1016/s0140-6736(11)61613-9
29 https://doi.org/10.1016/s0140-6736(12)60651-5
30 https://doi.org/10.1016/s1470-2045(07)70037-2
31 https://doi.org/10.1016/s1470-2045(11)70124-3
32 https://doi.org/10.1016/s1470-2045(15)00290-9
33 https://doi.org/10.1016/s1470-2045(15)00325-3
34 https://doi.org/10.1016/s1470-2045(16)30107-3
35 https://doi.org/10.1056/nejmoa021491
36 https://doi.org/10.1056/nejmoa032691
37 https://doi.org/10.1056/nejmoa060655
38 https://doi.org/10.1056/nejmoa061884
39 https://doi.org/10.1056/nejmoa065044
40 https://doi.org/10.1056/nejmoa066838
41 https://doi.org/10.1056/nejmoa0707330
42 https://doi.org/10.1056/nejmoa0708857
43 https://doi.org/10.1056/nejmoa072113
44 https://doi.org/10.1056/nejmoa1303989
45 https://doi.org/10.1056/nejmoa1309748
46 https://doi.org/10.1056/nejmra1601333
47 https://doi.org/10.1093/annonc/mdm454
48 https://doi.org/10.1097/jto.0b013e3181c7307e
49 https://doi.org/10.1158/1078-0432.ccr-08-2740
50 https://doi.org/10.1158/1078-0432.ccr-09-0717
51 https://doi.org/10.1158/1078-0432.ccr-11-1275
52 https://doi.org/10.1158/1078-0432.ccr-12-2535
53 https://doi.org/10.1158/1078-0432.ccr-13-0708
54 https://doi.org/10.1200/jco.2004.06.121
55 https://doi.org/10.1200/jco.2004.11.022
56 https://doi.org/10.1200/jco.2007.10.8332
57 https://doi.org/10.1200/jco.2007.11.5154
58 https://doi.org/10.1200/jco.2008.16.9847
59 https://doi.org/10.1200/jco.2008.19.0108
60 https://doi.org/10.1200/jco.2008.21.6994
61 https://doi.org/10.1200/jco.2009.23.9764
62 https://doi.org/10.1200/jco.2013.50.8267
63 https://doi.org/10.1200/jco.2015.60.9727
64 https://doi.org/10.3109/0284186x.2013.782103
65 https://doi.org/10.4161/cbt.29187
66 schema:datePublished 2017-12
67 schema:datePublishedReg 2017-12-01
68 schema:description BACKGROUND: Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal antibody have been registered for clinical use in advanced renal cell carcinoma. The VEGFR TKI, pazopanib, with a rather manageable toxicity profile, was preferred to sunitinib by mRCC patients. We investigate the combination of pazopanib and bevacizumab to determine the maximum tolerated dose (MTD) in mRCC and other advanced solid tumors. METHODS: In this bicentric phase I trial with a 3 + 3 + 3 dose-escalation design, patients received oral pazopanib once daily plus intravenous infusion of bevacizumab every 2 weeks from D15, at one of the four dose levels (DL) planned according to the occurrence of dose limiting toxicities (DLT). 400 and 600 mg pazopanib were respectively combined with 7.5 mg/kg bevacizumab in DL1 and DL2, and 600 and 800 mg pazopanib with 10 mg/kg bevacizumab in DL3 and DL4. Tumor response was evaluated every 8 weeks. Blood samples were assayed to investigate pazopanib pharmacokinetics. RESULTS: Twenty five patients including seven mRCC were enrolled. Nine patients received the DL1, ten received the DL2. No DLT were observed at DL1, five DLT at DL2, and 3 DLT in the six additional patients who received the DL1. A grade 3 microangiopathic hemolytic anemia syndrome was observed in four (16%) patients. Five (22%) patients achieved a partial response. The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion. CONCLUSIONS: The combination of pazopanib and bevacizumab induces angiogenic toxicity in patients without any pre-existing renal or vascular damage. Even if a marginal efficacy was reported with five (22%) patients in partial response in different tumor types, the toxicity profile compromises the development of this combination. TRIAL REGISTRATION: The study was retrospectively registered on ClinicalTrials.gov (number NCT01202032 ) on 2010, Sept 14th.
69 schema:genre research_article
70 schema:inLanguage en
71 schema:isAccessibleForFree true
72 schema:isPartOf N3cdf734870ed4bbb842f4ee7cb9760ba
73 N78ad0fb6f5a448209fe2a2a65a93ad2a
74 sg:journal.1024632
75 schema:name Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
76 schema:pagination 547
77 schema:productId N45ad736d136b49df82e140ac59021581
78 N45c1d0e27cf54f6b8da584f205d1c957
79 N7611f72cde5846e1a59ac493d84bdcbb
80 N94f74a251a5d4805871f3e9a6aebcb1f
81 Nf089249f866a4c898f3a53b99eadb3d5
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091206574
83 https://doi.org/10.1186/s12885-017-3527-7
84 schema:sdDatePublished 2019-04-11T10:35
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher N95b38caae02f41618a0d9b849b948155
87 schema:url https://link.springer.com/10.1186%2Fs12885-017-3527-7
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N023a7f49589b44edb857ec9bc06d3ba0 rdf:first sg:person.0723756046.31
92 rdf:rest N4d1bd2c06e9347079bf748d81390173b
93 N0f7724da3a4c4717a3af24f12038de14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Adult
95 rdf:type schema:DefinedTerm
96 N0fafbce12d7a4ab8b89e6850e71caa3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Humans
98 rdf:type schema:DefinedTerm
99 N17dfe252055442bf9240065f332cc184 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Bevacizumab
101 rdf:type schema:DefinedTerm
102 N25250acb70dd4cd0853084b3b3f044ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Middle Aged
104 rdf:type schema:DefinedTerm
105 N2599413de8b84b66b7932bd36732f922 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Combined Modality Therapy
107 rdf:type schema:DefinedTerm
108 N2941413c830b460d840ba8ce5ac01362 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Male
110 rdf:type schema:DefinedTerm
111 N3227aa7f77e44a3b8a0b49086aaeddd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Antineoplastic Combined Chemotherapy Protocols
113 rdf:type schema:DefinedTerm
114 N36886ec7413e43b19881d0bf903d39f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Aged
116 rdf:type schema:DefinedTerm
117 N392abedf434c4d929789479aa887b75c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Sulfonamides
119 rdf:type schema:DefinedTerm
120 N3cdf734870ed4bbb842f4ee7cb9760ba schema:issueNumber 1
121 rdf:type schema:PublicationIssue
122 N45ad736d136b49df82e140ac59021581 schema:name pubmed_id
123 schema:value 28810837
124 rdf:type schema:PropertyValue
125 N45c1d0e27cf54f6b8da584f205d1c957 schema:name doi
126 schema:value 10.1186/s12885-017-3527-7
127 rdf:type schema:PropertyValue
128 N4d1bd2c06e9347079bf748d81390173b rdf:first sg:person.01221677717.00
129 rdf:rest N7b0009b0490343b0bd1fed73cc2c6402
130 N75c3793e58064b098059c7f221033215 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Female
132 rdf:type schema:DefinedTerm
133 N7611f72cde5846e1a59ac493d84bdcbb schema:name nlm_unique_id
134 schema:value 100967800
135 rdf:type schema:PropertyValue
136 N782907f23c984748ad4a6520d12342a3 rdf:first sg:person.01225022325.73
137 rdf:rest Ndfc0930a4c204ea8864634707c6873ef
138 N78ad0fb6f5a448209fe2a2a65a93ad2a schema:volumeNumber 17
139 rdf:type schema:PublicationVolume
140 N7b0009b0490343b0bd1fed73cc2c6402 rdf:first sg:person.012307334207.98
141 rdf:rest Nd169c41ca3104b48a1bac026cab67e43
142 N8d73a2f57d78482a8ff592e24e02efb7 rdf:first sg:person.01312356242.78
143 rdf:rest N924471129a0d4003ba24c3ce27dd4008
144 N924471129a0d4003ba24c3ce27dd4008 rdf:first sg:person.011242133047.80
145 rdf:rest Nc2e65e54e28e46d79cf017dbf7875790
146 N94f74a251a5d4805871f3e9a6aebcb1f schema:name dimensions_id
147 schema:value pub.1091206574
148 rdf:type schema:PropertyValue
149 N95b38caae02f41618a0d9b849b948155 schema:name Springer Nature - SN SciGraph project
150 rdf:type schema:Organization
151 Nbba105ab39cb4b269e3163de5df23fa0 rdf:first sg:person.01333606250.74
152 rdf:rest Ncad29109422042a0b12949548ddf9a25
153 Nc2e65e54e28e46d79cf017dbf7875790 rdf:first sg:person.01356177754.57
154 rdf:rest N782907f23c984748ad4a6520d12342a3
155 Nc5a6260810d94f6ea53190c5db5c1bb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Kidney Neoplasms
157 rdf:type schema:DefinedTerm
158 Nc720c0a966b24f169453e83c766afbfb schema:name University Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France
159 rdf:type schema:Organization
160 Ncad29109422042a0b12949548ddf9a25 rdf:first sg:person.0616261742.66
161 rdf:rest N8d73a2f57d78482a8ff592e24e02efb7
162 Nd169c41ca3104b48a1bac026cab67e43 rdf:first sg:person.0602246235.37
163 rdf:rest Nbba105ab39cb4b269e3163de5df23fa0
164 Nd64aa83d5e02413a9d60f09cb16fe1af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Treatment Outcome
166 rdf:type schema:DefinedTerm
167 Ndfc0930a4c204ea8864634707c6873ef rdf:first sg:person.01304252172.82
168 rdf:rest rdf:nil
169 Nf089249f866a4c898f3a53b99eadb3d5 schema:name readcube_id
170 schema:value dc58ef9d3d7658c236388b94c962245d927321db9b75adec9773af9d70ae4f9d
171 rdf:type schema:PropertyValue
172 Nf364c7ca48824563b44efc9d2a666679 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Pyrimidines
174 rdf:type schema:DefinedTerm
175 Nfb66508769374dd9beacaf3b12879317 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Drug Monitoring
177 rdf:type schema:DefinedTerm
178 Nfda06d92fb144fe9ac2ec288986f8b07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Carcinoma, Renal Cell
180 rdf:type schema:DefinedTerm
181 Nff1e9da37dbc4d6f96512550dd2ae904 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Maximum Tolerated Dose
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
188 schema:name Clinical Sciences
189 rdf:type schema:DefinedTerm
190 sg:journal.1024632 schema:issn 1471-2407
191 schema:name BMC Cancer
192 rdf:type schema:Periodical
193 sg:person.011242133047.80 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
194 schema:familyName Metzger
195 schema:givenName Séverine
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011242133047.80
197 rdf:type schema:Person
198 sg:person.01221677717.00 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
199 schema:familyName Pérol
200 schema:givenName David
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221677717.00
202 rdf:type schema:Person
203 sg:person.01225022325.73 schema:affiliation https://www.grid.ac/institutes/grid.5842.b
204 schema:familyName Soria
205 schema:givenName Jean-Charles
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225022325.73
207 rdf:type schema:Person
208 sg:person.012307334207.98 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
209 schema:familyName Bahleda
210 schema:givenName Rastislav
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012307334207.98
212 rdf:type schema:Person
213 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
214 schema:familyName Escudier
215 schema:givenName Bernard
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
217 rdf:type schema:Person
218 sg:person.01312356242.78 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
219 schema:familyName Cassier
220 schema:givenName Philippe
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312356242.78
222 rdf:type schema:Person
223 sg:person.01333606250.74 schema:affiliation https://www.grid.ac/institutes/grid.15781.3a
224 schema:familyName Chatelut
225 schema:givenName Etienne
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333606250.74
227 rdf:type schema:Person
228 sg:person.01356177754.57 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
229 schema:familyName Blanc
230 schema:givenName Ellen
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356177754.57
232 rdf:type schema:Person
233 sg:person.0602246235.37 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
234 schema:familyName Hollebecque
235 schema:givenName Antoine
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602246235.37
237 rdf:type schema:Person
238 sg:person.0616261742.66 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
239 schema:familyName Boyle
240 schema:givenName Helen
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616261742.66
242 rdf:type schema:Person
243 sg:person.0723756046.31 schema:affiliation Nc720c0a966b24f169453e83c766afbfb
244 schema:familyName Négrier
245 schema:givenName Sylvie
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31
247 rdf:type schema:Person
248 sg:pub.10.1007/s00240-003-0346-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023624302
249 https://doi.org/10.1007/s00240-003-0346-x
250 rdf:type schema:CreativeWork
251 sg:pub.10.1007/s00280-013-2373-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011745965
252 https://doi.org/10.1007/s00280-013-2373-9
253 rdf:type schema:CreativeWork
254 sg:pub.10.1007/s00280-014-2455-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012606735
255 https://doi.org/10.1007/s00280-014-2455-3
256 rdf:type schema:CreativeWork
257 sg:pub.10.1007/s00280-014-2479-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041617704
258 https://doi.org/10.1007/s00280-014-2479-8
259 rdf:type schema:CreativeWork
260 sg:pub.10.1007/s10637-013-9976-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010470509
261 https://doi.org/10.1007/s10637-013-9976-1
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1016/j.ejca.2013.06.042 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040912245
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1016/s0140-6736(07)61904-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010511397
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1016/s0140-6736(11)61613-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052713041
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1016/s0140-6736(12)60651-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040046880
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1016/s1470-2045(07)70037-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021597703
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1016/s1470-2045(11)70124-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046924268
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1016/s1470-2045(15)00290-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048871630
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1016/s1470-2045(15)00325-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011519120
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1016/s1470-2045(16)30107-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031150467
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1056/nejmoa021491 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020803009
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1056/nejmoa032691 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014051315
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1056/nejmoa061884 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008302687
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1056/nejmoa066838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037798278
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1056/nejmoa0707330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036840499
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1056/nejmoa0708857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053513212
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1056/nejmoa072113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033842397
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1056/nejmoa1303989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030656737
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1056/nejmoa1309748 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006159778
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1056/nejmra1601333 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074211544
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1093/annonc/mdm454 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018847020
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1097/jto.0b013e3181c7307e schema:sameAs https://app.dimensions.ai/details/publication/pub.1047443465
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1158/1078-0432.ccr-08-2740 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025063112
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1158/1078-0432.ccr-09-0717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018539077
314 rdf:type schema:CreativeWork
315 https://doi.org/10.1158/1078-0432.ccr-11-1275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047556241
316 rdf:type schema:CreativeWork
317 https://doi.org/10.1158/1078-0432.ccr-12-2535 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009131859
318 rdf:type schema:CreativeWork
319 https://doi.org/10.1158/1078-0432.ccr-13-0708 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029146743
320 rdf:type schema:CreativeWork
321 https://doi.org/10.1200/jco.2004.06.121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001303596
322 rdf:type schema:CreativeWork
323 https://doi.org/10.1200/jco.2004.11.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000451221
324 rdf:type schema:CreativeWork
325 https://doi.org/10.1200/jco.2007.10.8332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000481419
326 rdf:type schema:CreativeWork
327 https://doi.org/10.1200/jco.2007.11.5154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027241718
328 rdf:type schema:CreativeWork
329 https://doi.org/10.1200/jco.2008.16.9847 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041483211
330 rdf:type schema:CreativeWork
331 https://doi.org/10.1200/jco.2008.19.0108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049557004
332 rdf:type schema:CreativeWork
333 https://doi.org/10.1200/jco.2008.21.6994 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006983294
334 rdf:type schema:CreativeWork
335 https://doi.org/10.1200/jco.2009.23.9764 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052849919
336 rdf:type schema:CreativeWork
337 https://doi.org/10.1200/jco.2013.50.8267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053397983
338 rdf:type schema:CreativeWork
339 https://doi.org/10.1200/jco.2015.60.9727 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016822150
340 rdf:type schema:CreativeWork
341 https://doi.org/10.3109/0284186x.2013.782103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039366876
342 rdf:type schema:CreativeWork
343 https://doi.org/10.4161/cbt.29187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072293145
344 rdf:type schema:CreativeWork
345 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
346 schema:name DITEP -Département d’Innovation Thérapeutiques et Essais Précoces, Institut Gustave Roussy, 94805, Villejuif Cedex, France
347 Department of Medical Oncology, Institut Gustave Roussy, 114, rue Edouard-Vaillant, 94805, Villejuif Cedex, France
348 rdf:type schema:Organization
349 https://www.grid.ac/institutes/grid.15781.3a schema:alternateName Paul Sabatier University
350 schema:name Institut Claudius Regaud, Inserm UMR1037 CRCT, Université Paul-Sabatier, 20/24 rue du Pont Saint-Pierre, 31052, Toulouse, France
351 rdf:type schema:Organization
352 https://www.grid.ac/institutes/grid.418116.b schema:alternateName Centre Léon Bérard
353 schema:name Clinical Research and Innovation Department, Centre Léon Bérard, F-69373, Lyon, Cedex 08, France
354 Medical Oncology Department, Centre Léon Bérard, F-69373, Lyon, Cedex 08, France
355 rdf:type schema:Organization
356 https://www.grid.ac/institutes/grid.5842.b schema:alternateName University of Paris-Sud
357 schema:name University of Paris Sud, Orsay, Institut Gustave Roussy, 94805, Villejuif Cedex, France
358 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...